TOLREMO was founded on pioneering expertise in non-mutational drug resistance to deliver a new wave of resistance-preventing precision therapies to patients with cancer. Their proprietary drug discovery engine enables the identification of novel drug resistance regulators and the development of small molecule therapies against these promising drug targets. TOLREMO’s therapies aim to complement standard cancer therapies to offer better response rates, longer survival and improved quality of life.
TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).
TOLREMO therapeutics has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, and existing investors…
| Building | C2 |
|---|---|
| Industry | Biotech |
| Employees | 7 |
| Founding year | 2017 |
Home 
About us 
Offer 
News 
